US92556V1061
© PR Newswire
15.12.2025
VTRS
LISTED
NASDAQ
Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back
News Preview
ETOBICOKE, ON, Dec. 15, 2025 /CNW/ -- Viatris Inc. (Nasdaq: VTRS) has been named one of the 2025 Best Workplaces™ in Ontario and one of the 2025 Best Workplaces™ for Giving Back in Canada. These recognitions highlight Viatris in Canada's commitment to fostering a culture where colleagues are enthusiastic about the work they do, feel valued, engage...
Themefolio
Profiler
Peergroup
© PR Newswire
06.12.2025
VTRS
LISTED
NASDAQ
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
News Preview
Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon LimitedTransaction Accelerates the Expiration of Biosimilars Non-Compete RestrictionsPITTSBURGH, Dec. 6, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has entered into definitive agreements with Biocon Limited ("Biocon") for the sale of V...
Themefolio
Profiler
Peergroup
© PR Newswire
24.11.2025
VTRS
LISTED
NASDAQ
Viatris to Participate in Upcoming Investor Conferences
News Preview
PITTSBURGH, Nov. 24, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in December 2025.
The Company will participat...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
20.11.2025
VTRS
LISTED
NASDAQ
Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorgestellt wurden
News Preview
BRÜSSEL, 20. November 2025 /PRNewswire/ -- Zu Beginn der Weltwoche zur Sensibilisierung für Antibiotikaresistenzen (AMR) zeigt der globale Bericht der Weltgesundheitsorganisation zur Überwachung von Antibiotikaresistenzen für 2025, dass weltweit jede sechste bakterielle Infektion mittlerweile gegen Antibiotika re...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
13.11.2025
VTRS
LISTED
NASDAQ
Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025
News Preview
PITTSBURGH, Nov. 13, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best Workplaces™ in 2025. The list of 25 global leaders was selected from organizations that participated in Great Place To Work's employee survey process, with over 9 mi...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
VTRS
LISTED
NASDAQ
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
News Preview
Delivers Total Revenues in Line With Expectations, Reflecting Strong Execution of its Global Business
Makes Late-Stage Pipeline Progress Including NDA Submission for Low-Dose Estrogen Weekly Patch...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
VTRS
LISTED
NASDAQ
Viatris Announces Quarterly Dividend
News Preview
PITTSBURGH, Nov. 4, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on November 3, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 15, 2025, to shareholders...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2025
VTRS
LISTED
NASDAQ
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
News Preview
Strengthens Viatris' Presence in Japan With the Addition of Two Innovative Assets Targeting Areas of Significant Unmet Medical Need
Leverages Existing Infrastructure and Expertise in Central Nervous System Therapy Area...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
VTRS
LISTED
NASDAQ
Viatris to Participate in Upcoming Investor Conferences
News Preview
PITTSBURGH, Oct. 13, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in November 2025.
The Company will participate in a fireside chat at the UBS Global Healthcare Conference 202...
Themefolio
Profiler
Peergroup
© PR Newswire
08.10.2025
VTRS
LISTED
NASDAQ
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row
News Preview
PITTSBURGH, Oct. 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2025. This is the fifth year in a row that Viatris has received this recognition, which is presented by Forbes and Statista, the world...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2025
VTRS
LISTED
NASDAQ
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025
News Preview
PITTSBURGH, Oct. 1, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.
Investors and the general public are invited to liste...
Themefolio
Profiler
Peergroup
© PR Newswire
19.08.2025
VTRS
LISTED
NASDAQ
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer
News Preview
PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Sec...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
11.08.2025
VTRS
LISTED
NASDAQ
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
News Preview
Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines
Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity
PITTSBURGH, Aug. 11, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare compa...
Themefolio
Profiler
Peergroup
© PR Newswire
01.08.2025
VTRS
LISTED
NASDAQ
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
News Preview
Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data
PITTSBURGH, Aug. 1, 2025 /PRNewswire/ -- Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (...
Themefolio
Profiler
Peergroup
© PR Newswire
18.07.2025
VTRS
LISTED
NASDAQ
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
News Preview
PITTSBURGH, July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete re...
Themefolio
Profiler
Peergroup
© PR Newswire
15.07.2025
VTRS
LISTED
NASDAQ
Viatris Certified as a Great Place to Work® in Canada
News Preview
ETOBICOKE, ON, July 15, 2025 /CNW/ -- Viatris Inc. (Nasdaq: VTRS) has been certified as a Great Place to Work® in Canada. This recognition highlights Viatris' commitment to fostering a culture where colleagues are enthusiastic about the work they do and feel valued, engaged and motivated.
Great Place to Work® is the global authority on workplace...
Themefolio
Profiler
Peergroup
© PR Newswire
26.06.2025
VTRS
LISTED
NASDAQ
Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
News Preview
MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision
Safety Profile Consistent With Previous Clinical Trials And No Treatment-Related Serious Adverse Events Reported In This Study
Targeting Application To U.S. FDA In Second Half of 2025
PITTSBURGH...
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
VTRS
LISTED
NASDAQ
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025
News Preview
PITTSBURGH, June 12, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results....
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
VTRS
LISTED
NASDAQ
Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, both dates inclusive (the “Class Period”). Viatris describes itself as a “global healthcare company, which engages in the provision of h...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
VTRS
LISTED
NASDAQ
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NASDAQ: VTRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
VTRS
LISTED
NASDAQ
Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
News Preview
MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo
Results Showed Patient-Reported Functional Benefit in Treating Significant Chronic Night Driving Impairment in Keratorefractive Patients With Reduced Mesopic Vision, a Condition With No Current FDA-Approved Therapi...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
VTRS
LISTED
NASDAQ
VIATRIS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NasdaqGS: VTRS), if they purchased the Company’s securitie...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
VTRS
LISTED
NASDAQ
Deadline Soon: Viatris Inc. (VTRS) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming June 3, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) securities between August 8, 2024, to February 26, 2025, inclusive (the “Class Pe...
Themefolio
Profiler
Peergroup
© PR Newswire
27.05.2025
VTRS
LISTED
NASDAQ
Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada
News Preview
ETOBICOKE, ON, May 27, 2025 /CNW/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch in Canada of Gen-Clozapine orally disintegrating tablets (ODT) (12.5 mg, 25 mg, 50 mg, 100 mg and 200 mg), providing a new treatment option for treatment-resistant schizophrenia patients. This marks the first availability in C...
Themefolio
Profiler
Peergroup
© PR Newswire
22.05.2025
VTRS
LISTED
NASDAQ
Viatris to Participate in Upcoming Investor Conferences
News Preview
PITTSBURGH, May 22, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in June 2025.
The Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, at 8:10 a.m. ET.
In addition, the C...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
VTRS
LISTED
NASDAQ
Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook
News Preview
Delivers Total Revenues in Line With Expectations Demonstrating Strength of the Base Business
Makes Significant Pipeline Progress With Three Positive Phase 3 Data Readouts
Returns More Than $450 Million in Capital to Shareholders Year-to-Date and Reaffirms 2025 Capital Allocation Priorities
PITTSBURGH, May 8, 2025 /PRNewswire/ -- ...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
VTRS
LISTED
NASDAQ
Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential
News Preview
Treatment With XULANE LO Low Estrogen Dose Achieved Primary and All Secondary Efficacy and Safety Endpoints
Results Demonstrated Potential Best-In-Class Patch Performance
New Drug Application Submission to U.S. FDA Anticipated in the Second Half of 2025
PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare comp...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
VTRS
LISTED
NASDAQ
Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
News Preview
All Primary and Secondary Endpoints Were Met in Both Phase 3 Studies
In Both Acute Pain Models, MR-107A-02 Demonstrated Statistically Significant and Clinically Meaningful Improvement in Pain Compared to Placebo, Significant Reduction in Opioid Usage and Superior Pain Control Versus the Opioid Arm
Targeting New Drug Application Submission to U.S....
Themefolio
Profiler
Peergroup
© PR Newswire
07.05.2025
VTRS
LISTED
NASDAQ
Viatris Announces Quarterly Dividend
News Preview
PITTSBURGH, May 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 5, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 16, 2025, to shareholders of record as of the close of business on May...
Themefolio
Profiler
Peergroup
© PR Newswire
05.05.2025
VTRS
LISTED
NASDAQ
Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
News Preview
Directors Rajiv Malik and Harry Korman to Retire at the End of Their Current Terms
PITTSBURGH, May 5, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Frank D'Amelio and Michael Severino, M.D., have been appointed as the newest members of Viatris...
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2025
VTRS
LISTED
NASDAQ
Viatris to Present at the BofA Securities 2025 Healthcare Conference
News Preview
PITTSBURGH, April 25, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, will present at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV, on Tuesday, May 13, 2025. The company's presentation will begin at 5 p.m. PT / 8 p.m. ET.
A live webcast of the event at can be found at investor.viatris.com. An arch...
Themefolio
Profiler
Peergroup
© PR Newswire
21.04.2025
VTRS
LISTED
NASDAQ
Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder
News Preview
Aiming to address a significant unmet need for which no other approved treatment option is available for generalized anxiety disorder patients in Japan
PITTSBURGH, April 21, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has filed applications to the Ministry of Health, Labor and Welfare (MHLW) f...
Themefolio
Profiler
Peergroup
© PR Newswire
14.04.2025
VTRS
LISTED
NASDAQ
Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer
News Preview
PITTSBURGH, April 14, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company's Executive Leadership Team....
Themefolio
Profiler
Peergroup
© BusinessWire
14.04.2025
VTRS
LISTED
NASDAQ
VTRS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, both dates inclusive (the “Class Period”), have until June 3, 2025 to seek appointment as lead plaintiff of the Viatris class action lawsuit. Captioned Quinn v. Viatris Inc., No. 25-cv-...
Themefolio
Profiler
Peergroup
© BusinessWire
10.04.2025
VTRS
LISTED
NASDAQ
VTRS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, both dates inclusive (the “Class Period”), have until June 3, 2025 to seek appointment as lead plaintiff of the Viatris class action lawsuit. Captioned Quinn v. Viatris...
Themefolio
Profiler
Peergroup
© BusinessWire
10.04.2025
VTRS
LISTED
NASDAQ
Deadline Alert: Viatris Inc. (VTRS) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming June 3, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) securities between August 8, 2024, to February 26, 2025, inclusive (the “Class Period”)...
Themefolio
Profiler
Peergroup
© BusinessWire
09.04.2025
VTRS
LISTED
NASDAQ
Law Offices of Frank R. Cruz Encourages Viatris Inc. (VTRS) Investors to Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) securities between August 8, 2024, to February 26, 2025, inclusive (the “Class Period”). Viatris investors have until June 3, 2025 to file a lead plaintiff motion.
IF Y...
Themefolio
Profiler
Peergroup
© BusinessWire
09.04.2025
VTRS
LISTED
NASDAQ
Deadline Approaching: Viatris Inc. (VTRS) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming June 3, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) securities between August 8, 2024, to February 26, 2025, inclusive (the “Class Period”).
IF YOU ARE AN INVESTOR WHO S...
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
VTRS
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Viatris Inc. (VTRS) Investors To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) securities between August 8, 2024, to February 26, 2025, inclusive (the “Class Per...
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
VTRS
LISTED
NASDAQ
Law Offices of Howard G. Smith Encourages Viatris Inc. (VTRS) Investors To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) securities between August 8, 2024, to February 26, 2025, inclusive (the “Class Period”). Viatris investors have until June 3, 2025 to file a lead plaintiff motion.
IF YOU...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
VTRS
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) and reminds investors of the June 3, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruq...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
VTRS
LISTED
NASDAQ
Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, both dates inclusive (the “Class Period”). Viatris describes itself as a “global healthcare company, which engages in the provision of h...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
VTRS
LISTED
NASDAQ
VIATRIS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NasdaqGS: VTRS), if they purchased the Company’s securities be...
Themefolio
Profiler
Peergroup
© PR Newswire
07.04.2025
VTRS
LISTED
NASDAQ
Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims
News Preview
PITTSBURGH, April 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) (the "Company") today announced it has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes against the Company and certain of its subsidiaries. While the Company's presence in the U.S. opioids market is very small,...
Themefolio
Profiler
Peergroup
© BusinessWire
04.04.2025
VTRS
LISTED
NASDAQ
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NASDAQ: VTRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors...
Themefolio
Profiler
Peergroup
© BusinessWire
02.04.2025
VTRS
LISTED
NASDAQ
VTRS Investors Have Opportunity to Join Viatris Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viatris Inc. (“Viatris” or “the Company”) (NASDAQ: VTRS) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose...
Themefolio
Profiler
Peergroup
© PR Newswire
28.03.2025
VTRS
LISTED
NASDAQ
Viatris to Report First Quarter 2025 Financial Results on May 8, 2025
News Preview
PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.
Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.c...
Themefolio
Profiler
Peergroup
© BusinessWire
14.03.2025
VTRS
LISTED
NASDAQ
Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation – VTRS
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public.
So What: If you purchased Viatris securities you may...
Themefolio
Profiler
Peergroup
© BusinessWire
12.03.2025
VTRS
LISTED
NASDAQ
Securities Fraud Investigation Into Viatris Inc. (VTRS) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON VIATRIS INC. (...
Themefolio
Profiler
Peergroup
© BusinessWire
12.03.2025
VTRS
LISTED
NASDAQ
Viatris Inc. (VTRS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN VIATRIS INC. (VTRS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING...
Themefolio
Profiler
Peergroup
© BusinessWire
11.03.2025
VTRS
LISTED
NASDAQ
Securities Fraud Investigation Into Viatris Inc. (VTRS) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON VIATRIS INC. (VTRS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YO...
Themefolio
Profiler
Peergroup
© PR Newswire
05.03.2025
VTRS
LISTED
NASDAQ
Viatris to Present at the Barclays 27th Annual Global Healthcare Conference
News Preview
PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.
A live webcast of the event at can be found at investor.viatris.com. An archiv...
Themefolio
Profiler
Peergroup
© PR Newswire
27.02.2025
VTRS
LISTED
NASDAQ
Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance
News Preview
PITTSBURGH, Feb. 27, 2025 /PRNewswire/ --
Meets 2024 Guidance for Total Revenues, Adjusted EBITDA and Adjusted EPS; Exceeds 2024 Guidance for Free Cash Flow [1]Reports 2024 Total Revenues of $14.7 Billion, U.S. GAAP Net Loss of $(634) Million, Adjusted EBITDA of $4.7 Billion, U.S. GAAP Diluted EPS Loss of $(0.5...
Themefolio
Profiler
Peergroup
© PR Newswire
27.02.2025
VTRS
LISTED
NASDAQ
Viatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend
News Preview
PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on ...
Themefolio
Profiler
Peergroup
© PR Newswire
03.02.2025
VTRS
LISTED
NASDAQ
Viatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
News Preview
PITTSBURGH, Feb. 3, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.
Investors and the general public are invited to listen to a live webcast of the...
Themefolio
Profiler
Peergroup
© PR Newswire
07.01.2025
VTRS
LISTED
NASDAQ
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
PITTSBURGH, Jan. 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025. The company's presentation and fireside chat will begin at 8:15 a.m. PT / 11:15 a.m. ET.
A live webcast...
Themefolio
Profiler
Peergroup
© PR Newswire
18.12.2024
VTRS
LISTED
NASDAQ
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology
News Preview
Biomarker data from CARE study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the Annals of the Rheumatic Diseases
PITTSBURGH, Dec. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
VTRS
LISTED
NASDAQ
Viatris Reports Third Quarter Financial Results for 2024
News Preview
PITTSBURGH, Nov. 7, 2024 /PRNewswire/ --
Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1] Strong New Product Revenues of $133 Million Drove Growth Across Segments U.S. GAAP Net Earnings were $95 Million; Adju...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2024
VTRS
LISTED
NASDAQ
Viatris Announces Third Quarter 2024 Dividend
News Preview
PITTSBURGH, Nov. 5, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 13, 2024, to shareholders of record as of the close of busin...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2024
VTRS
LISTED
NASDAQ
Viatris Named to Forbes' World's Top Companies for Women 2024 List
News Preview
PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' World's Top Companies for Women 2024 List. This award is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider.
"At Viatris, diverse perspective...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
